Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

Functional characteristics of N8, a new recombinant FVIII

(2010) M. L. S. CHRISTIANSEN et al.   HAEMOPHILIA

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice

(2009) J. Pan et al.   BLOOD

Purification and characterization of a new recombinant factor VIII (N8)

(2009) L. THIM et al.   HAEMOPHILIA

A ferric chloride induced arterial injury model used as haemostatic effect model

(2009) F. MØLLER et al.   HAEMOPHILIA

Effect of Route of Administration of Human Recombinant Factor VIII on Its Immunogenicity in Hemophilia A Mice

(2009) Aaron Peng et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

In vivo models of haemophilia – status on current knowledge of clinical phenotypes and therapeutic interventions

(2008) K. ØVLISEN et al.   HAEMOPHILIA

Prevention of haemarthrosis in a murine model of acute joint bleeding

(2008) L. A. VALENTINO et al.   HAEMOPHILIA

Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice

(2008) K. ØVLISEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

(2008) V. S. BLANCHETTE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS